Somatrem: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 33: | Line 33: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
{{No image}} | {{No image}} | ||
Latest revision as of 18:47, 18 March 2025
Somatrem is a recombinant DNA derived form of human growth hormone (hGH). It is primarily used in the treatment of growth hormone deficiency in children. Somatrem is produced by E. coli bacteria that have been modified by the addition of the gene for human growth hormone.
Mechanism of Action[edit]
Somatrem works by binding to the growth hormone receptor (GHR) on the surface of cells. This binding triggers a series of reactions within the cell that lead to the growth-promoting effects of the hormone. These effects include increased protein synthesis, increased cell division and growth, and increased metabolism of fats and carbohydrates.
Side Effects[edit]
Like all medications, somatrem can cause side effects. The most common side effects include injection site reactions, joint pain, muscle pain, and fluid retention. Less common but more serious side effects can include diabetes, carpal tunnel syndrome, and high blood pressure.
Contraindications[edit]
Somatrem is contraindicated in patients with active malignancy, diabetic retinopathy, and in those with hypersensitivity to somatrem or any of its excipients.
Dosage and Administration[edit]
The dosage of somatrem is individualized for each patient based on the patient's weight and growth response. It is administered by subcutaneous injection.
See Also[edit]
References[edit]
<references />


